Nifedipine attenuates systemic and renal vasoconstriction during nitric oxide inhibition in humans

Hypertension

Volumn 29, Issue 5, 1997, Pages 1192-1198

  Dijkhorst Oei, Lioe Ting ^a   Rabelink, Ton J ^b   Boer, Peter ^b   Koomans, Hein A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

blood pressure; calcium channel blockers; glomerular filtration rate; L NMMA

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; N(G) METHYLARGININE; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY VASCULAR RESISTANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0030991628     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1192     Document Type: Article

References (42)

1. Lahera V, Salom MG, Miranda-Guardiola F, Moncada S, Romero JC. Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol. 1991;261:F1033-F1037.
2. Sigmon DH, Beierwaltes WH. Angiotensin II: nitric oxide interaction and the distribution of blood flow. Am J Physiol. 1993;265: R1276-R1283.
3. Huang M, Manning RD Jr, LeBlanc MH, Hester RL. Overall hemodynamic studies after the chronic inhibition of endothelial-derived nitric oxide in rats. Am J Hypertens. 1995;8:358-364.
4. Salazar FJ, Pinilla JM, Lopez F, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension. 1992;20:113-117.
5. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, U-Na, and vasoactive hormones in healthy humans. Am J Physiol. 1996;270:F845-F851.
6. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl Med. 1990;323:22-27.
7. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471.
8. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GSJ. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet. 1993;342: 242-243.
9. Beierwaltes WH, Potter DL, Carretero OA, Sigmon DH. Nitric oxide synthesis inhibition blocks reversal of two-kidney, one clip renovascular hypertension after unclipping. Hypertension. 1995;25: 174-179.
10. Wakabayashi Y, Kikawada R. Effect of L-arginine on myoglobin-induced acute renal failure in the rabbit. Am J Physiol. 1996;270: F784-F789.
11. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
12. Diederich D, Yang Z, Luscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol. 1992;2:1291-1297.
13. Kuriyama H, Kitamura K, Nabata H. Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev. 1995;47:387-573.
14. Warner TD, Schmidt HH, Murad F. Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. Am J Physiol. 1992;262:H1600-H1605.
15. 1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Hypertension. 1995;26:752-757.
16. Wang YX, Zhou T, Pang CC. A comparison of the inhibitory effects of sodium nitroprusside, pinacidil and nifedipine on pressor response to NG-nitro-L-arginine. Br J Pharmacol. 1993;108: 398-404.
17. Baylis C, Masilamani S, Losonczy G, Samsell L, Harton P, Engels K. Blood pressure (BP) and renal vasoconstrictor responses to acute blockade of nitric oxide: persistence of renal vasoconstriction despite normalization of BP with either verapamil or sodium nitroprusside. J Pharmacol Exp Ther. 1995;274:1135-1141.
18. Nafrialdi N, Jover B, Mimran A. Endogenous vasoactive systems and the pressor effect of acute N omega-nitro-L-arginine methyl ester administration. J Cardiovasc Pharmacol. 1994;23:765-771.
19. Bank N, Aynedjian HS, Khan GA. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension. 1994;24:322-328.
20. Kung CF, Moreau P, Takase H, Luscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta: prevention by trandolapril and verapamil. Hypertension. 1995;26: 744-751.
21. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens. 1993;11:1375-1380.
22. Hansen J, Jacobsen TN, Victor RG. Is nitric oxide involved in the tonic inhibition of central sympathetic outflow in humans? Hypertension. 1994;24:439-444.
23. Clarkson PBM, Lim PO, MacDonald TM. Influence of basal nitric oxide secretion on cardiac function in man. Br J Clin Pharmacol. 1995;40:299-305.
24. Heyrowski A. A new method for determination of inulin in plasma and urine. Clin Chim Acta. 1956;1:470-474.
25. Waugh WH, Beall PT. Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. Kidney Int. 1974;5:429-436.
26. Schultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest. 1992;90: 1718-1725.
27. Toda N, Kitamura Y, Okamura T. Neural mechanism of hypertension by nitric oxide synthase inhibitor in dogs. Hypertension. 1993;21:3-8.
28. Loeb AL, Longnecker DE. Inhibition of endothelium-derived relaxing factor-dependent circulatory control in intact rats. Am J Physiol. 1992;262:H1494-H1500.
29. Denton KM, Anderson WP. Intrarenal haemodynamic and glomerular responses to inhibition of nitric oxide formation in rabbits. J Physiol (Lond). 1994;475:159-167.
30. Majid DS, Godfrey M, Grisham MB, Navar LG. Relation between pressure natriuresis and urinary excretion of nitrate/nitrite in anesthetized dogs. Hypertension. 1995;25:860-865.
31. Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol. 1993;264: F212-F215.
32. Ito S, Ren Y. Evidence for the role of nitric oxide in macula densa control of glomerular hemodynamics. J Clin Invest. 1993;92: 1093-1098.
33. Vos PF, Koomans HA, Boer P, Dorhout Mees EJ. Effects of angiotensin II on renal sodium handling and diluting capacity in man, pretreated with high salt diet and enalapril. Nephrol Dial Transplant. 1992;7:991-996.
34. Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994; 46:376-381.
35. Fenoy FJ, Ferrer P, Carbonell L, Garcia Salom M. Role of nitric oxide on papillary blood flow and pressure natriuresis. Hypertension. 1995;25:408-414.
36. Stoos BA, Carretero OA, Farhy RD, Scicli G, Garvin JL. Endothelium-derived relaxing factor inhibits transport and increases cGMP content in cultured mouse cortical collecting duct cells. J Clin Invest. 1992;89:761-765.
37. Soward AL, Vanhaleweyk GL, Serruys PW. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease: a review. Drugs. 1986;32:66-101.
38. Heller J, Horacek V. The effect of two different calcium antagonists on the glomerular haemodynamics in the dog. Pflugers Arch. 1990; 415:751-755.
39. Sluiter HE, Wetzels JF, Huysmans FT, Koene RA. The natriuretic effect of the dihydropyridine calcium antagonist felodipine: a placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. J Cardiovasc Pharmacol. 1987;10(suppl 10):S154-S161.
40. Kaasjager KAH, Van Rijn HJM, Koomans HA, Rabelink TJ. Interactions of nifedipine with the renovascular effects of endothelin in humans. J Pharmacol Exp Ther. 1995;275:306-311.
41. DiBona GF, Sawin LL. Renal tubular site of action of felodipine. J Pharmacol Exp Ther. 1984;228:420-425.
42. Jin JS, Wilde DW, Webb RC, D'Alecy LG. Calcium channel activity increased by plasma from ischemic hindlimbs of rats: role of an endogenous NO synthase inhibitor. Am J Physiol. 1996;270: H1484-H1492.